p.87 抽出テキスト

139. Leening MJ, Ferket BS, Steyerberg EW, Kavousi M, Deckers JW, Nieboer D, et al. Sex differences in lifetime risk and first manifestation of cardiovascular disease: prospective population based cohort study. BMJ 2014;349:g5992. https://doi.org/10.1136/bmj.g5992 140. Ference BA, Bhatt DL, Catapano AL, Packard CJ, Graham I, Kaptoge S, et al. Association of genetic variants related to combined exposure to lower low-density lipoproteins and lower systolic blood pressure with lifetime risk of cardiovascular disease. JAMA 2019;322:1381–91. https://doi.org/10.1001/jama.2019.14120 141. Kannel WB. Risk stratification in hypertension: new insights from the Framingham study. Am J Hypertens 2000;13:S3–10. https://doi.org/10.1016/s0895-7061(99)00252-6 142. Weycker D, Nichols GA, O’Keeffe-Rosetti M, Edelsberg J, Khan Z, Kaura S, et al. Risk-factor clustering and cardiovascular disease risk in hypertensive patients. Am J Hypertens 2007;20:599–607. https://doi.org/10.1016/j.amjhyper.2006.10.013 143. Constanti M, Floyd CN, Glover M, Boffa R, Wierzbicki AS, McManus RJ. Cost-effectiveness of initiating pharmacological treatment in stage one hypertension based on 10-year cardiovascular disease risk: a Markov modeling study. Hypertension 2021;77:682–91. https://doi.org/10.1161/hypertensionaha.120.14913 144. Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990–2015. JAMA 2017;317:165–82. https://doi.org/10.1001/jama.2016.19043 145. Karmali KN, Ning H, Goff DC, Lloyd-Jones DM. Identifying individuals at risk for cardiovascular events across the spectrum of blood pressure levels. J Am Heart Assoc 2015;4:e002126. https://doi.org/10.1161/jaha.115.002126 146. Liu J, Li Y, Ge J, Yan X, Zhang H, Zheng X, et al. Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial. Lancet 2024;404:245–55. https://doi.org/10.1016/S0140-6736(24) 01028-6 147. Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97:1837–47. https://doi.org/10.1161/01.cir.97.18.1837 148. Sussman J, Vijan S, Hayward R. Using benefit-based tailored treatment to improve the use of antihypertensive medications. Circulation 2013;128:2309–17. https://doi.org/10. 1161/circulationaha.113.002290 149. Karmali KN, Lloyd-Jones DM, van der Leeuw J, Goff DC, Yusuf S, Zanchetti A, et al. Blood pressure-lowering treatment strategies based on cardiovascular risk versus blood pressure: a meta-analysis of individual participant data. PLoS Med 2018;15: e1002538. https://doi.org/10.1371/journal.pmed.1002538 150. Gaziano TA, Steyn K, Cohen DJ, Weinstein MC, Opie LH. Cost-effectiveness analysis of hypertension guidelines in South Africa: absolute risk versus blood pressure level. Circulation 2005;112:3569–76. https://doi.org/10.1161/circulationaha.105.535922 151. Basu S, Sussman JB, Hayward RA. Black-white cardiovascular disease disparities after target-based versus personalized benefit-based lipid and blood pressure treatment. MDM Policy Pract 2017;2:2381468317725741. https://doi.org/10. 1177/2381468317725741 152. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351: 1296–305. https://doi.org/10.1056/NEJMoa041031 153. Klooster CCV, Bhatt DL, Steg PG, Massaro JM, Dorresteijn JAN, Westerink J, et al. Predicting 10-year risk of recurrent cardiovascular events andcardiovascular interventions in patients with established cardiovascular disease: results from UCC-SMART and REACH. Int J Cardiol 2021;325:140–8. https://doi.org/10.1016/j.ijcard.2020.09.053 154. Kaasenbrood L, Boekholdt SM, van der Graaf Y, Ray KK, Peters RJG, Kastelein JJP, et al. Distribution of estimated 10-year risk of recurrent vascular events and residual risk in a secondary prevention population. Circulation 2016;134:1419–29. https://doi.org/10. 1161/circulationaha.116.021314 155. Eisen A, Bhatt DL, Steg PG, Eagle KA, Goto S, Guo J, et al. Angina and future cardiovascular events in stable patients with coronary artery disease: insights from the Reduction of Atherothrombosis for Continued Health (REACH) registry. J Am Heart Assoc 2016;5:e004080. https://doi.org/10.1161/jaha.116.004080 156. Taylor CJ, Roalfe AK, Iles R, Hobbs FD. Ten-year prognosis of heart failure in the community: follow-up data from the Echocardiographic Heart of England Screening (ECHOES) study. Eur J Heart Fail 2012;14:176–84. https://doi.org/10.1093/eurjhf/hfr170 157. Shah KS, Xu H, Matsouaka RA, Bhatt DL, Heidenreich PA, Hernandez AF, et al. Heart failure with preserved, borderline, and reduced ejection fraction: 5–year outcomes. J Am Coll Cardiol 2017;70:2476–86. https://doi.org/10.1016/j.jacc.2017.08.074 158. Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham heart study. Circulation 1998; 98:946–52. https://doi.org/10.1161/01.cir.98.10.946 159. Pandey A, Patel KV, Vongpatanasin W, Ayers C, Berry JD, Mentz RJ, et al. Incorporation of biomarkers into risk assessment for allocation of antihypertensive medication according to the 2017 ACC/AHA high blood pressure guideline: a pooled cohort analysis. Circulation 2019;140:2076–88. https://doi.org/10.1161/circulationaha.119.043337 160. Mulnier HE, Seaman HE, Raleigh VS, Soedamah-Muthu SS, Colhoun HM, Lawrenson RA, et al. Risk of myocardial infarction in men and women with type 2 diabetes in the UK: a cohort study using the general practice research database. Diabetologia 2008;51:1639–45. https://doi.org/10.1007/s00125-008-1076-y 161. Soedamah-Muthu SS, Fuller JH, Mulnier HE, Raleigh VS, Lawrenson RA, Colhoun HM. High risk of cardiovascular disease in patients with type 1 diabetes in the U.K.: a cohort study using the general practice research database. Diabetes Care 2006;29:798–804. https://doi.org/10.2337/diacare.29.04.06.dc05-1433 162. Wong ND, Glovaci D, Wong K, Malik S, Franklin SS, Wygant G, et al. Global cardiovascular disease risk assessment in United States adults with diabetes. Diab Vasc Dis Res 2012;9:146–52. https://doi.org/10.1177/1479164112436403 163. Paquette M, Bernard S, Cariou B, Hegele RA, Genest J, Trinder M, et al. Familial hypercholesterolemia-risk-score: a new score predicting cardiovascular events and cardiovascular mortality in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2021;41:2632–40. https://doi.org/10.1161/atvbaha.121.316106 164. SCORE2-Diabetes Working Group and the ESC Cardiovascular Risk Collaboration. SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe. Eur Heart J 2023;44:2544–56. https://doi.org/10.1093/eurheartj/ ehad260 165. SCORE Working Group and the ESC Cardiovascular Risk Collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J 2021;42:2439–54. https://doi.org/10.1093/eurheartj/ehab309 166. SCORE OP working group and ESC Cardiovascular Risk Collaboration. SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions. Eur Heart J 2021;42:2455–67. https://doi.org/ 10.1093/eurheartj/ehab312 167. Pignone M, Phillips CJ, Elasy TA, Fernandez A. Physicians’ ability to predict the risk of coronary heart disease. BMC Health Serv Res 2003;3:13. https://doi.org/10.1186/1472- 6963-3-13 168. Grover SA, Lowensteyn I, Esrey KL, Steinert Y, Joseph L, Abrahamowicz M. Do doctors accurately assess coronary risk in their patients? Preliminary results of the coronary health assessment study. BMJ 1995;310:975–8. https://doi.org/10.1136/bmj.310. 6985.975 169. Friedmann PD, Brett AS, Mayo-Smith MF. Differences in generalists’ and cardiologists’ perceptions of cardiovascular risk and the outcomes of preventive therapy in cardiovascular disease. Ann Intern Med 1996;124:414–21. https://doi.org/10.7326/0003- 4819-124-4-199602150-00005 170. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021;42: 3227–337. https://doi.org/10.1093/eurheartj/ehab484 171. Xie X, Atkins E, Lv J, Bennett A, Neal B, Ninomiya T, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 2016;387:435–43. https://doi.org/10.1016/s0140-6736(15) 00805-3 172. Herrett E, Gadd S, Jackson R, Bhaskaran K, Williamson E, van Staa T, et al. Eligibility and subsequent burden of cardiovascular disease of four strategies for blood pressurelowering treatment: a retrospective cohort study. Lancet 2019;394:663–71. https:// doi.org/10.1016/s0140-6736(19)31359-5 173. Matsushita K, Kaptoge S, Hageman SHJ, Sang Y, Ballew SH, Grams ME, et al. Including measures of chronic kidney disease to improve cardiovascular risk prediction by SCORE2 and SCORE2-OP. Eur J Prev Cardiol 2023;30:8–16. https://doi.org/10.1093/ eurjpc/zwac176 174. Gerdts E, Sudano I, Brouwers S, Borghi C, Bruno RM, Ceconi C, et al. Sex differences in arterial hypertension. Eur Heart J 2022;43:4777–88. https://doi.org/10.1093/eurheartj/ ehac470 175. Brown MC, Best KE, Pearce MS, Waugh J, Robson SC, Bell R. Cardiovascular disease risk in women with pre-eclampsia: systematic review and meta-analysis. Eur J Epidemiol 2013;28:1–19. https://doi.org/10.1007/s10654-013-9762-6 176. Honigberg MC, Zekavat SM, Aragam K, Klarin D, Bhatt DL, Scott NS, et al. Long-term cardiovascular risk in women with hypertension during pregnancy. J Am Coll Cardiol 2019;74:2743–54. https://doi.org/10.1016/j.jacc.2019.09.052 177. Leon LJ, McCarthy FP, Direk K, Gonzalez-Izquierdo A, Prieto-Merino D, Casas JP, et al. Preeclampsia and cardiovascular disease in a large UK pregnancy cohort of linked electronic health records: a CALIBER study. Circulation 2019;140:1050–60. https://doi.org/ 10.1161/circulationaha.118.038080 178. Haug EB, Horn J, Markovitz AR, Fraser A, Klykken B, Dalen H, et al. Association of conventional cardiovascular risk factors with cardiovascular disease after hypertensive disorders of pregnancy: analysis of the Nord-Trøndelag health study. JAMA Cardiol 2019; 4:628–35. https://doi.org/10.1001/jamacardio.2019.1746 179. Wu P, Haththotuwa R, Kwok CS, Babu A, Kotronias RA, Rushton C, et al. Preeclampsia and future cardiovascular health: a systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes 2017;10:e003497. https://doi.org/10. 1161/circoutcomes.116.003497 180. Kramer CK, Campbell S, Retnakaran R. Gestational diabetes and the risk of cardiovascular disease in women: a systematic review and meta-analysis. Diabetologia 2019;62: 905–14. https://doi.org/10.1007/s00125-019-4840-2 181. Kyriacou H, Al-Mohammad A, Muehlschlegel C, Foster-Davies L, Bruco MEF, Legard C, et al. The risk of cardiovascular diseases after miscarriage, stillbirth, and induced abortion: a systematic review and meta-analysis. Eur Heart J Open 2022;2:oeac065. https://doi.org/10.1093/ehjopen/oeac065 Downloaded from academic.oup.com/eurheartj/article/45/38/3912/7741010 by guest on 07 October 2026